Serum eosinophil cationic protein: a prognostic factor for early postoperative recurrence of nasal polyps

Lu, Pin-Ching; Lee, Ta‐Jen; Huang, Chi‐Che; Chang, Po-Huang; Chen, Yiwei; Fu, Chia‐Hsiang

doi:10.1002/alr.22664

Cited by 25 publications

(10 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients with ECRS or CRS with nasal polyps have been shown to have a significantly higher level of ECP in nasal tissue than patients with non-eosinophilic CRS and control patients [ 33 34 ]. In addition, serum ECP may be a feasible predictor for early postoperative recurrence of nasal polyps [ 35 ]. That evidence suggested that ECRS pathophysiology does not depend on the mere presence of eosinophil but on the degranulation of eosinophils.…”

Section: Discussionmentioning

confidence: 99%

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma

Kobayashi

Nagase

Sugimoto

et al. 2021

Asia Pacific Allergy

View full text Add to dashboard Cite

Background Mepolizumab, a humanized antibody targeting interleukin-5, decreases the number of blood eosinophils and the frequency of exacerbation of severe asthma. Galectin-10 is a protein within the cytoplasm of eosinophils and constitutes Charcot-Leyden crystals, which promotes key features of asthma. However, the relationship between time kinetics and clinical response of eosinophil-derived molecules such as galectin-10 or eosinophil cationic protein (ECP) has not been precisely investigated. Objective This study aimed to clarify the precise time course of the levels of serum galectin-10 and ECP after mepolizumab treatment and to analyze the relationship between the levels of eosinophil-derived molecules and the clinical background or response to mepolizumab treatment. Methods This multicenter, prospective open-label study recruited 20 patients with severe eosinophilic asthma. Mepolizumab was administered every 4 weeks for 32 weeks and the levels of various biomarkers were serially analyzed. Results The serum galectin-10 and ECP significantly and rapidly decreased 4 weeks after initial administration of mepolizumab. In contrast, basophil count, fractional exhaled nitric oxide, and the serum total IgE level were unchanged during treatment. Asthma Control Questionnaire-5, Asthma Health Questionnaire-33, and Lund-Mackay scores significantly improved after mepolizumab treatment. Both high ECP and eosinophil count related to better response in forced expiratory volume in 1 second (FEV 1 ) and measurable ECP level at 4 weeks after administration of mepolizumab related to the further improvement in FEV 1 toward week 32. No significant difference in improvement in FEV 1 was observed in galectin-10 high group. The level of ECP at baseline was significantly related to the higher prevalence of nasal polyp and Lund-Mackay score. Conclusion This study was the first to show that the levels of serum galectin-10 decreases after initial administration of mepolizumab. The significant relationship between serum ECP and better response in FEV 1 suggested the potential role of serum ECP as a predictive biomarker for the efficacy of mepolizumab (UMIN000030466).

show abstract

Section: Discussionmentioning

confidence: 99%

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma

Kobayashi

Nagase

Sugimoto

et al. 2021

Asia Pacific Allergy

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that IL-5 and eosinophil cationic protein are ideal biomarkers for predicting the efficacy of clinical treatment for chronic rhinosinusitis with nasal polyps; 28 furthermore, serum eosinophil cationic protein is a useful indicator for predicting the early recurrence of nasal polyps. 29 A double-blind clinical trial confirmed that oral glucocorticoid therapy reduced the levels of IL-5 and eosinophil cationic protein in nasal secretions from patients with chronic rhinosinusitis with nasal polyps. 30 In our study, after stratification of patients with chronic rhinosinusitis with nasal polyps according to peripheral blood eosinophil percentage, we found that the use of glucocorticoids did not significantly reduce the levels of IL-5 or eosinophil cationic protein in peripheral blood and nasal secretions from patients with non-eosinophilic chronic rhinosinusitis with nasal polyps.…”

Section: Discussionmentioning

confidence: 88%

Use of peripheral blood eosinophils to guide post-operative glucocorticoid therapy in patients with chronic rhinosinusitis with nasal polyps: a randomised, controlled trial

et al. 2022

View full text Add to dashboard Cite

Objective This study aimed to explore the utility of the eosinophil percentage in peripheral blood for guiding post-operative glucocorticoid therapy in patients with chronic rhinosinusitis with nasal polyps. Methods Forty-four patients with chronic rhinosinusitis with nasal polyps underwent functional endoscopic sinus surgery and were randomly divided into two groups. Patients in the standard treatment group used oral and nasal spray glucocorticoids. In the biomarker treatment group, patients with peripheral blood eosinophil percentage values less than 3.05 per cent did not receive glucocorticoid treatment, whereas patients with values 3.05 per cent or above were part of the standard treatment group. Visual Analogue Scale, Sino-Nasal Outcome Test-22 scores, endoscopic Lund–Kennedy scores, eosinophils, interleukin-5 and eosinophil cationic protein in peripheral blood, and nasal secretions were measured. Results After functional endoscopic sinus surgery, the Visual Analogue Scale, Sino-Nasal Outcome Test-22 and Lund–Kennedy scores were significantly reduced in both groups; there were no significant differences in those indicators between the groups during the three follow-up visits. Conclusion Peripheral blood eosinophil percentage offers a potential biomarker to guide post-operative glucocorticoid therapy in patients with chronic rhinosinusitis with nasal polyps.

show abstract

“…Endoscopic sinus surgery was performed for CRS management, applying a bidirectional method that combines anterior-to-posterior and posterior-to-anterior approaches 21 . After surgery, all patients were scheduled for regular follow-ups at our outpatient department as previously described 22 . Briefly, patients were treated with Augmentin ® 30 mg/kg/day for 1 week postoperatively, and at 2 weeks after surgery, nasal corticosteroid spray (mometasone furoate, 200 μg/day) and nasal saline irrigation (250 ml once daily) were initiated for 3 months.…”

Section: Methodsmentioning

confidence: 99%

Elevated Serum Aspergillus Fumigatus-Specific Immunoglobulin G in Type 2 Chronic Rhinosinusitis

Chang¹,

Lee²,

Huang³

et al. 2023

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: Aspergillus fumigatus -specific immunoglobulin G (Af-sIgG) has been applied to diagnose allergic bronchopulmonary aspergillosis, a hypersensitivity reaction to the colonization of the fungus in the lower airways. In the upper airways, it has been reported to be involved in allergic fungal rhinosinusitis and local fungal rhinosinusitis. However, in primary chronic rhinosinusitis (CRS), a more common upper airway disease, the role of Af-sIgG remains unclear. Objective: The aim of our study was to investigate the role of serum Af-sIgG levels in primary CRS patients. Methods: We prospectively recruited patients diagnosed with bilateral primary CRS and patients with nasal septal deviation as the non-CRS group. Patients in the primary CRS group were further classified into two endotypes, including type 2 (T2) and non-T2 groups. Serum samples collected were sent for Af-sIgG analysis. Potential factors and surgical outcomes were analyzed. Results: Forty-eight patients with a diagnosis of primary CRS (including 28 with T2 and 20 with non-T2 CRS) and 22 patients in the non-CRS group were recruited. The T2 CRS group had significantly higher serum Af-sIgG levels than the non-T2 CRS group (odds ratio 10.2 with Af-sIgG more than 27.6 mg/L; p < 0.001). Further multivariate logistic regression showed that the serum Af-sIgG level was the independent factor for early disease recurrence within one year in primary CRS patients. The optimal cutoff value of the serum Af-sIgG level to predict postoperative recurrence was 27.1 mg/L (odds ratio 15.1, p = 0.013). Conclusions: We suggest that the serum Af-sIgG level is a practical marker to detect T2 inflammation and the surgical outcome of primary CRS. By applying this feasible test, we may be able to achieve optimal treatment for every individual with primary CRS. This study may provide physicians with a reference for future clinical applications in dealing with primary CRS.

show abstract

Serum eosinophil cationic protein: a prognostic factor for early postoperative recurrence of nasal polyps

Cited by 25 publications

References 58 publications

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma

Use of peripheral blood eosinophils to guide post-operative glucocorticoid therapy in patients with chronic rhinosinusitis with nasal polyps: a randomised, controlled trial

Elevated Serum Aspergillus Fumigatus-Specific Immunoglobulin G in Type 2 Chronic Rhinosinusitis

Contact Info

Product

Resources

About